publication venue for
- 412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors 2010
- 491 NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly 2010
- 58 Development and characterization of novel orally available Hypoxiainducible factor (HIF) signaling inhibitors as dual-mechanism cancer therapeutics 2010
- P71 Vascular endothelial growth factor (VEGF) inhibition and erythropoiesis – a missing link? 2009
- 18LBA A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients 2009
- 7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) 2009
- 7014 A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive Castrate Resistant Prostate Cancer (CRPC) 2009
- 7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC) 2009
- 8506 Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience 2009
- 112 POSTER A clinical chemistry approach for identifying biomarkers as surrogate endpoints in therapy directed against chemokine mediated metastasis 2008
- 206 POSTER Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC) 2008
- 382 POSTER Comparison of phase I trial (P1T) abstract quality between the EORTC-NCI-AACR and ASCO meetings 2008
- 405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers 2008
- Skeletal-related event (SRE) history, bone metastasis location and number affect SRE risk and patient survival in metastatic breast cancer 2008
- 188 INVITED Lessons and questions from the overview 2007
- 304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors 2007
- 31 INVITED Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer 2007
- 3503 ORAL Adding external beam to HDR-intraluminal brachytherapy, improves palliation of oesophageal cancer: a prospective randomized, multicentre trial of the International Atomic Energy Agency 2007
- 4060 POSTER Annual ibandronic acid to prevent gonadotropin included bone loss in men with prostate cancer 2007
- 515 POSTER Zoledronic Acid (ZOL) treatment may improve survival in patients with lung cancer and high baseline N-telopeptide levels: a multivariate Cox regression analysis 2007
- 6550 POSTER A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer 2007
- O-17 Implanted gold seeds for tumour bed localisation and image-guided radiotherapy 2007
- 47 POSTER A phase II study of Sorafenib (BAY 43-9006) in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC): final results 2006
- 550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors 2006
- Effects of AZD2171 on pharmacokinetics (PK) of carboplatin (C) and paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group 2006
- A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) 2005
- A Phase II study of Temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer - NCICCTG IND 160 2005
- Breast cancer patients with persistently increased bone resorption 2005
- Development of fractionated stereotactic radiotherapy for meningioma 2005
- Phase II study of Sorafenib (BAY 43-9006) in combination with Gemcitabine in recurrent epithelial ovarian cancer - a study of the PMH phase II consortium 2005
- Randomised trial of standard 2D radiotherapy (RT) versus 3D intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy 2005
- Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy 2005
- The influence of mentorship on research productivity in oncology 2005
- The rapid uptake of concurrent chemotherapy for cervix cancer patients treated with curative radiation 2005
- 208 HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial 2004
- Mammography screening pathology, a new challenge for the histopathologist − a two year review on the first mammography screening project in Germany 2004
- 142 Phase II study of imatinib mesylate in salivary gland adenoid cystic carcinoma 2003
- 393 A phase II study of OSI-774 given in combination with carboplatin in patients with recurrent ovarian cancer (NCIC IND.149). 2:118-118. 2004
- 408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157). 2:122-122. 2004
- 159 Phase II study of OSI-774 given in combination with carboplatin in patients (pts) with recurrent epithelial ovarian cancer (EOC): NCIC ctg Ind.149. 1:S51-S51. 2003
- 191 Phase II trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer. 1:S60-S61. 2003
- 905 Documenting symptom palliation with chemotherapy using the LCSS-Meso: Results from the randomized trial of pemetrexed plus cisplatin vs cisplatin alone in patients with malignant pleural mesothelloma. 1:S272-S272. 2003